Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Greydon Arthur"'
Autor:
Nicholas R. Jette, Mehul Kumar, Suraj Radhamani, Greydon Arthur, Siddhartha Goutam, Steven Yip, Michael Kolinsky, Gareth J. Williams, Pinaki Bose, Susan P. Lees-Miller
Publikováno v:
Cancers, Vol 12, Iss 3, p 687 (2020)
Poly-ADP ribose polymerase (PARP) inhibitors are currently used in the treatment of several cancers carrying mutations in the breast and ovarian cancer susceptibility genes BRCA1 and BRCA2, with many more potential applications under study and in cli
Externí odkaz:
https://doaj.org/article/a9c064e50c564fcc891dc9fca9dc689f
Autor:
Greydon Arthur, Siddhartha Goutam, Suraj Radhamani, Anthony Bolyos, L. Petersen, Ruiqiong Ye, D. Gwyn Bebb, Susan P. Lees-Miller, Pinaki Bose, Nicholas Jette
Publikováno v:
British Journal of Cancer
Background Up to 40% of lung adenocarcinoma have been reported to lack ataxia-telangiectasia mutated (ATM) protein expression. We asked whether ATM-deficient lung cancer cell lines are sensitive to poly-ADP ribose polymerase (PARP) inhibitors and det
Autor:
Pinaki Bose, Siddhartha Goutam, Tarek A. Bismar, Nicholas Jette, Suraj Radhamani, Greydon Arthur, Yaping Yu, Steven Yip, Ruiqiong Ye, Michael Paul Kolinsky, Susan P. Lees-Miller, Mehul Kumar
BackgroundThe ataxia telangiectasia mutated (ATM) protein kinase is mutated in several human cancers, presenting potential opportunities for targeted cancer therapy. We previously reported that the poly-ADP ribose polymerase (PARP) inhibitor olaparib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c7fa4d65666885c32c1bceb1bdab8b7
https://doi.org/10.1101/2020.03.13.991166
https://doi.org/10.1101/2020.03.13.991166
Autor:
Pinaki Bose, Siddhartha Goutam, Michael Paul Kolinsky, Steven Yip, Nicholas Jette, Mehul Kumar, Greydon Arthur, Suraj Radhamani, Susan P. Lees-Miller, Gareth J. Williams
Publikováno v:
Cancers
Cancers, Vol 12, Iss 3, p 687 (2020)
Cancers, Vol 12, Iss 3, p 687 (2020)
Poly-ADP ribose polymerase (PARP) inhibitors are currently used in the treatment of several cancers carrying mutations in the breast and ovarian cancer susceptibility genes BRCA1 and BRCA2, with many more potential applications under study and in cli
Autor:
Nicholas R. Jette, Suraj Radhamani, Greydon Arthur, Ruiqiong Ye, Siddhartha Goutam, Anthony Bolyos, Lars F. Petersen, Pinaki Bose, D. Gwyn Bebb, Susan P. Lees-Miller
Publikováno v:
British Journal of Cancer. 122:1872-1872
This Article was originally published under Nature Research’s License to Publish, but has now been made available under a CC BY 4.0 license. This has now been corrected in both the PDF and HTML versions of the Article.